A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

October 15, 2025

Study Completion Date

July 22, 2026

Conditions
Generalized Pustular PsoriasisErythrodermic Psoriasis
Interventions
DRUG

TAK-279

Specified drug on specified days.

Trial Locations (20)

Unknown

Nagoya City University Hospital, Nagoya

Fujita Health University Hospital, Toyoake

Kimitsu Chuo Hospital, Kisarazu

Juntendo University Urayasu Hospital, Urayasu

Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu

Isesaki Municipal Hospital, Isesaki

Kobe University Hospital, Kobe

Tokai University Hospital, Isehara

Mie University Hospital, Tsu

Kansai Medical University Hospital, Hirakata

Saitama Medical University Hospital, Iruma

St.Luke's International Hospital, Chūō

Teikyo University Hospital, Itabashi-ku

The Jikei University Hospital, Minato-ku

Tokyo Medical University Hospital, Shinjuku-ku

Fukuoka University Hospital, Fukuoka

University Hospital, Kyoto Prefectural University of Medicine, Kyoto

Okayama University Hospital, Okayama

Nippon Life Hospital, Osaka

Osaka Metropolitan University Hospital, Osaka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY